Dataset from A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy

The primary objective of the study is to assess the efficacy of Intravenous (IV) BG00010
(Neublastin) in improving pain in painful lumbar radiculopathy participants when administered
3 times per week for 1 week.

The secondary objectives of this study in this study population are as follows: To explore
the duration of the effect of BG00010 in improving pain; To explore the dose response curve
on pain reduction; To assess the safety and tolerability of BG00010; To assess the serum
exposure to BG00010.